Abstract: Nutritional formulas are provided which comprise isolated soy protein wherein the isolated soy protein has a phytate content of 100 mg per liter or less; and the isolated soy protein has a degree of hydrolysis between 5 and 20%.

Abstract: Methods for the treatment of short bowel syndrome in patients in need thereof are provided, comprising the administration to the patients of an effective amount of a formulation comprising arachidonic acid and docosahexanoic acid.

Abstract: The invention disclosed herein comprises fat compositions primarily for use in nutritionally complete infant formulas in which the constituent palmitic acid oils and lauric acid oils are corandomized. The invention additionally includes such corandomized fat compositions with medium-chain triglycerides added, particularly for use in nutritional products for preterm or low birthweight infants. The invention further includes such fat compositions in which the constituent palmitic acid oils and oleic acid oils are corandomized. Such corandomization of two or more oils yields a mixture of triglycerides having a substantially different chemical makeup than that of the native oils themselves or than the native oils when randomized individually. Corandomization of the palmitic acid oils and the lauric acid oils or of the palmitic acid oils and the oleic acid oils affords an economical means of providing a very highly absorbed fat composition.

Abstract: 2-(2,3-Dihydro-1,4-benzodioxin-2-yl)-4,5-dihydro-1H-imidazole, or a pharmaceutically acceptable salt thereof, is useful in the treatment of hyperprolactinemic states in warm-blooded animals.

Abstract: The octapeptide ##STR1## where the A groups are hydrogen or a dithioether bond and salts thereof inhibit gastric and pancreatic secretions and reduce gastrointestinal blood flow in treatment of peptic ulcer disease, acute pancreatitis and Zollinger-Ellison preoperational therapy.

Abstract: Administration of the compound 1-cis-2-(.alpha.-dimethylamino-m-hydroxybenzyl)cyclohexanol inhibits release of prolactin.

Abstract: Three polypeptides of the formulae [des-Ala.sup.1 -Gly.sup.2 ], Ala.sup.5, Ser.sup.6 -SRIF, Met.sup.7 -SRIF and [des-Ala.sup.1 -Gly.sup.2 -Lys.sup.4 ], (3-mercapto-1-oxopropyl).sup.3 -SRIF possessing gastric anti-secretory activity are useful anti-ulcer agents.

Abstract: The administration of the analgesic 13.beta.-amino-5,6,7,8,9,10,11,12-octahydro-5.alpha.-methyl-5,11-methanobe nzocyclodecen-3-ol to warm-blooded animals stimulates prolactin release.

Abstract: Administration of the opiate antagonist (1)-.alpha.-dimethylamino-.alpha.-(cis-2-benzoyloxycyclohexyl)-m-cresol inhibits release of prolactin without significantly inhibiting the release of growth hormone.

Abstract: Prolactin release is stimulated by parenteral administration of a pentapeptide of the formula:H-Tyr-Gly-Gly-Phe-Met-OH IorH-Tyr-Gly-Gly-Phe-Leu-OH IIor a non-toxic pharmacologically acceptable acid addition salt thereof.